Table 1.
Dietary supplement use of the study population and according to cancer sites of cancer survivorsa
| All | Female | Male | ||||
|---|---|---|---|---|---|---|
| Number | Dietary supplement use % (SE) | Number | Dietary supplement use % (SE) | Number | Dietary supplement use % (SE) | |
| Cancer-free individuals | 10,387 | 22.1 (0.6) | 6154 | 26.0 (0.7) | 4233 | 18.1 (0.8) |
| Cancer survivors | 400 | 33.3 (2.8) | 260 | 37.0 (3.6) | 140 | 26.7 (4.7) |
| P valueb | < 0.001 | 0.001 | 0.04 | |||
| By cancer site | ||||||
| Stomach | 71 | 29.8 (6.1) | 27 | 38.3 (11.4) | 44 | 23.9 (7.0) |
| Cervix or corpus uteri | 67 | 38.1 (7.2) | 67 | 38.1 (7.2) | 0 | – |
| Thyroid | 63 | 31.7 (6.5) | 54 | 31.7 (7.1) | 9 | 31.6 (16.3) |
| Breast | 59 | 55.9 (7.0) | 59 | 55.9 (7.0) | 0 | – |
| Colorectal | 52 | 22.5 (5.9) | 27 | 18.5 (8.1) | 25 | 26.6 (8.6) |
| Bladder | 14 | 28.7 (4.0) | 5 | 23.1 (0.0) | 9 | 31.5 (5.9) |
| Lung | 13 | 23.0 (11.4) | 4 | 49.6 (28.3) | 9 | 15.7 (5.4) |
| Prostate | 12 | 19.4 (7.0) | 0 | – | 12 | 19.4 (7.0) |
| Liver | 11 | 25.8 (6.4) | 2 | 0.0 | 9 | 28.5 (7.1) |
| Renal | 9 | 0.0 | 4 | 0.0 | 5 | 0.0 |
| Othersc | 46 | 29.2 (6.0) | 20 | 25.1 (12.7) | 26 | 32.0 (8.4) |
aCancer survivors with multiple cancer sites were counted multiple times; 11 participants had been diagnosed with cancer at two sites, and 3 participants had been diagnosed with cancer at three sites among the 400 cancer survivors
bRao-Scott chi-square p values were obtained using PROC SURVEYFREQ to compare the proportion of dietary supplement use between cancer survivors and cancer-free individuals
cOthers included 19 cancer sites (e.g., larynx, lymphoma, skin, ovarian, and esophageal)